References
- Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. 2021. Immunological basis of the endometriosis: the complement system as a potential therapeutic target. Front Immunol. 11:1–16.
- Ajona D, Ortiz-Espinosa S, Pio R. 2019. Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment. Semin Cell Dev Biol. 85:153–63.
- Allegretti M, Moriconi A, Beccari A, Bitondo R, Bizzarri C, Bertini R, Colotta F. 2012. Targeting C5a: recent advances in drug discovery. Curr Med Chem. 12(2):217–36.
- American Society for Reproductive. 1997. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 67(5):817–21.
- Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, De Negri P, Di Gennaro C, Pagano A, Allegorico E, et al. 2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 24(7):40.
- Fassbender A, D’Hooghe T, Mihalyi A, Kyama C, Simsa P, Lessey BA. 2009. Plasma C3a-des-Arg levels in women with and without endometriosis. Am J Reprod Immunol. 62(3):187–95.
- Guo R-F, Ward PA. 2005. Role of C5a in inflammatory responses. Annu Rev Immunol. 23(1):821–52.
- Hawksworth OA, Li XX, Coulthard LG, Wolvetang EJ, Woodruff TM. 2017. New concepts on the therapeutic control of complement anaphylatoxin receptors. Mol Immunol. 89:36–43.
- Karadadas E, Hortu I, Ak H, Ergenoglu AM, Karadadas N, Aydin HH. 2020. Evaluation of complement system proteins C3a, C5a and C6 in patients of endometriosis. Clin Biochem. 81:15–19.
- Králíčková M, Fiala L, Losan P, Tomes P, Vetvicka V. 2018. Altered immunity in endometriosis: what came first? Immunol Invest. 47(6):569–82.
- Nothnick WB. 2001. Treating endometriosis as an autoimmune disease. Fertil Steril. 76(2):223–31.
- Quadros AU, Cunha TM. 2016. C5a and pain development: an old molecule, a new target. Pharmacol Res. 112:58–67.
- Rahal D, Andrade F, Nisihara R. 2021. Insights into the role of complement system in the pathophysiology of endometriosis. Immunol Lett. 231:43–48.
- Vitiello A, La Porta R, D’Aiuto V, Ferrara F. 2021. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 82(4):264–69.
- Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, et al. 2020. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2(12):e764–73.
- Zelek WM, Morgan BP. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Front Immunol. 11:1–14.
- Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. 2018. Endometriosis. Nat Rev Dis Prim. 4(1):9.